Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ERAS |
---|---|---|
09:32 ET | 6987 | 2.73 |
09:34 ET | 1218 | 2.69 |
09:36 ET | 892 | 2.675 |
09:38 ET | 900 | 2.65 |
09:39 ET | 8095 | 2.64 |
09:41 ET | 3900 | 2.63 |
09:43 ET | 61864 | 2.615 |
09:45 ET | 44652 | 2.6 |
09:48 ET | 24936 | 2.58 |
09:50 ET | 17290 | 2.575 |
09:52 ET | 4186 | 2.59 |
09:54 ET | 1137 | 2.585 |
09:56 ET | 1660 | 2.59 |
09:57 ET | 3401 | 2.585 |
09:59 ET | 800 | 2.585 |
10:01 ET | 4233 | 2.59 |
10:03 ET | 600 | 2.59 |
10:06 ET | 2650 | 2.585 |
10:08 ET | 6241 | 2.57 |
10:10 ET | 67193 | 2.565 |
10:12 ET | 4906 | 2.555 |
10:14 ET | 4136 | 2.555 |
10:15 ET | 1041 | 2.555 |
10:17 ET | 975 | 2.55 |
10:19 ET | 6783 | 2.54 |
10:21 ET | 626 | 2.54 |
10:24 ET | 600 | 2.545 |
10:26 ET | 4446 | 2.555 |
10:28 ET | 2503 | 2.545 |
10:30 ET | 600 | 2.545 |
10:32 ET | 1796 | 2.54 |
10:33 ET | 900 | 2.545 |
10:35 ET | 10059 | 2.545 |
10:37 ET | 5239 | 2.555 |
10:39 ET | 1267 | 2.555 |
10:42 ET | 3513 | 2.545 |
10:44 ET | 700 | 2.545 |
10:46 ET | 2087 | 2.54 |
10:48 ET | 1641 | 2.545 |
10:50 ET | 5225 | 2.53 |
10:51 ET | 10319 | 2.525 |
10:53 ET | 2196 | 2.53 |
10:55 ET | 14698 | 2.54 |
10:57 ET | 2840 | 2.535 |
11:00 ET | 1500 | 2.535 |
11:02 ET | 1600 | 2.53 |
11:04 ET | 2304 | 2.54 |
11:06 ET | 2871 | 2.525 |
11:08 ET | 5504 | 2.525 |
11:09 ET | 13260 | 2.52 |
11:11 ET | 300 | 2.52 |
11:13 ET | 793 | 2.515 |
11:15 ET | 8105 | 2.525 |
11:18 ET | 176707 | 2.545 |
11:20 ET | 2213 | 2.545 |
11:22 ET | 4494 | 2.55 |
11:24 ET | 390 | 2.555 |
11:26 ET | 4758 | 2.55 |
11:27 ET | 786 | 2.555 |
11:29 ET | 1330 | 2.55 |
11:31 ET | 1999 | 2.555 |
11:33 ET | 6431 | 2.56 |
11:36 ET | 1617 | 2.57 |
11:38 ET | 1551 | 2.57 |
11:40 ET | 703 | 2.57 |
11:42 ET | 1300 | 2.565 |
11:44 ET | 5092 | 2.575 |
11:45 ET | 4467 | 2.565 |
11:47 ET | 1525 | 2.565 |
11:49 ET | 500 | 2.565 |
11:51 ET | 17097 | 2.58 |
11:54 ET | 1679 | 2.575 |
11:56 ET | 1080 | 2.575 |
11:58 ET | 5773 | 2.58 |
12:00 ET | 955 | 2.575 |
12:02 ET | 1259 | 2.58 |
12:03 ET | 810 | 2.58 |
12:05 ET | 13109 | 2.585 |
12:07 ET | 937 | 2.585 |
12:09 ET | 5761 | 2.58 |
12:12 ET | 1000 | 2.58 |
12:14 ET | 1200 | 2.585 |
12:16 ET | 700 | 2.585 |
12:18 ET | 1001 | 2.585 |
12:20 ET | 1525 | 2.585 |
12:21 ET | 6326 | 2.58 |
12:23 ET | 5080 | 2.57 |
12:25 ET | 2577 | 2.565 |
12:27 ET | 400 | 2.565 |
12:30 ET | 2207 | 2.555 |
12:32 ET | 4120 | 2.565 |
12:34 ET | 1200 | 2.56 |
12:36 ET | 3240 | 2.56 |
12:38 ET | 300 | 2.555 |
12:39 ET | 400 | 2.555 |
12:41 ET | 9933 | 2.545 |
12:43 ET | 200 | 2.545 |
12:45 ET | 2192 | 2.53 |
12:48 ET | 1611 | 2.53 |
12:50 ET | 1590 | 2.525 |
12:52 ET | 6100 | 2.535 |
12:54 ET | 655 | 2.535 |
12:56 ET | 8794 | 2.555 |
12:57 ET | 300 | 2.555 |
12:59 ET | 2000 | 2.545 |
01:01 ET | 400 | 2.54 |
01:03 ET | 1328 | 2.535 |
01:06 ET | 268 | 2.53 |
01:08 ET | 2900 | 2.525 |
01:10 ET | 1710 | 2.525 |
01:14 ET | 300 | 2.52 |
01:15 ET | 700 | 2.525 |
01:17 ET | 3514 | 2.515 |
01:19 ET | 863 | 2.51 |
01:21 ET | 300 | 2.51 |
01:24 ET | 4600 | 2.51 |
01:26 ET | 10197 | 2.51 |
01:28 ET | 100 | 2.515 |
01:30 ET | 200 | 2.515 |
01:33 ET | 5361 | 2.52 |
01:35 ET | 561 | 2.525 |
01:37 ET | 300 | 2.525 |
01:39 ET | 100 | 2.525 |
01:42 ET | 100 | 2.53 |
01:44 ET | 1053 | 2.52 |
01:46 ET | 1043 | 2.525 |
01:48 ET | 100 | 2.525 |
01:50 ET | 13440 | 2.54 |
01:51 ET | 2465 | 2.545 |
01:53 ET | 533 | 2.54 |
01:55 ET | 200 | 2.55 |
01:57 ET | 931 | 2.545 |
02:00 ET | 3058 | 2.555 |
02:02 ET | 200 | 2.56 |
02:04 ET | 800 | 2.56 |
02:06 ET | 10238 | 2.56 |
02:08 ET | 5509 | 2.57 |
02:09 ET | 342 | 2.56 |
02:15 ET | 1207 | 2.565 |
02:18 ET | 1567 | 2.57 |
02:20 ET | 350 | 2.565 |
02:22 ET | 600 | 2.565 |
02:24 ET | 700 | 2.565 |
02:26 ET | 724 | 2.57 |
02:27 ET | 811 | 2.57 |
02:29 ET | 1250 | 2.565 |
02:31 ET | 11874 | 2.575 |
02:33 ET | 847 | 2.575 |
02:36 ET | 5650 | 2.565 |
02:38 ET | 1330 | 2.56 |
02:40 ET | 1900 | 2.555 |
02:44 ET | 5585 | 2.545 |
02:45 ET | 1050 | 2.545 |
02:47 ET | 1600 | 2.56 |
02:49 ET | 1200 | 2.555 |
02:51 ET | 300 | 2.555 |
02:54 ET | 100 | 2.555 |
02:56 ET | 500 | 2.56 |
02:58 ET | 4031 | 2.565 |
03:00 ET | 4604 | 2.56 |
03:02 ET | 11038 | 2.575 |
03:03 ET | 900 | 2.575 |
03:05 ET | 9034 | 2.575 |
03:07 ET | 200 | 2.575 |
03:09 ET | 500 | 2.575 |
03:12 ET | 200 | 2.575 |
03:14 ET | 200 | 2.58 |
03:16 ET | 5231 | 2.565 |
03:18 ET | 1300 | 2.565 |
03:20 ET | 750 | 2.565 |
03:21 ET | 517 | 2.565 |
03:23 ET | 1000 | 2.565 |
03:25 ET | 500 | 2.56 |
03:27 ET | 2450 | 2.565 |
03:30 ET | 300 | 2.565 |
03:32 ET | 4193 | 2.565 |
03:34 ET | 3580 | 2.565 |
03:36 ET | 2015 | 2.565 |
03:38 ET | 25540 | 2.575 |
03:39 ET | 1100 | 2.575 |
03:41 ET | 200 | 2.58 |
03:43 ET | 1975 | 2.585 |
03:45 ET | 2434 | 2.585 |
03:48 ET | 1305 | 2.585 |
03:50 ET | 758 | 2.59 |
03:52 ET | 2400 | 2.59 |
03:54 ET | 5473 | 2.585 |
03:56 ET | 33620 | 2.59 |
03:57 ET | 71826 | 2.59 |
03:59 ET | 288646 | 2.59 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Erasca Inc | 771.2M | -2.8x | --- |
Nuvation Bio Inc | 766.6M | -1.1x | --- |
89Bio Inc | 783.7M | -3.7x | --- |
Arrivent Biopharma Inc | 789.3M | -9.7x | --- |
Rapport Therapeutics Inc | 749.1M | -11.5x | --- |
Replimune Group Inc | 748.8M | -3.6x | --- |
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled a wholly owned or controlled RAS/MAPK pathway-focused pipeline in the industry, which is focused on modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes three clinical-stage programs, such as a pan-RAF inhibitor, an ERK inhibitor, and a central nervous system (CNS)-penetrant EGFR inhibitor, and additional discovery-stage programs targeting other key oncogenic drivers. Its lead product candidate is naporafenib, a pan-RAF inhibitor with the potential for patients with NRAS-mutated (NRASm) melanoma, RAS Q61X solid tumors, and other RAS/MAPK pathway-driven tumors.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $771.2M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 282.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.92 |
Book Value | $2.10 |
P/E Ratio | -2.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.